China approves two-dose schedule for GSK’s cervical cancer drug

UK pharma giant GSK said China’s National Medical Products Administration has approved a two-dose vaccine schedule for its Cervarix treatment in girls aged between 9 to 14 years for the prevention of cervical cancer.
In 2020, there were approximately 110,000 new cases of cervical cancer and 59,000 deaths due to the disease in China, GSK said on Friday.

Featured News

This Week’s Most Read

Wealth DFM